Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma

British Journal of Dermatology

Volumn 134, Issue 2, 1996, Pages 269-275

  Wang, Y L ^a   Uhara, H ^a   Yamazaki, Y ^a   Nikaido, T ^a   Saida, T ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS; PRIORITY JOURNAL;

CARRIER PROTEINS; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; CYTOPLASM; HUMANS; MELANOMA; NEOPLASM PROTEINS; NEVUS, PIGMENTED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; SKIN NEOPLASMS;

EID: 0030040533     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb07612.x     Document Type: Article

References (27)

1. Kamb A, Gruis NA, Weaver-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-40.
2. Nobori T, Miura K, Wu DJ et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
4. Ohta M, Nagai H, Shimizu M et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 1994; 54: 5269-72.
5. Solomon MJ. Activation of the various cyclin/CDC2 protein kinases. Curr Opin Cell Biol 1993; 5: 180-6.
6. Nigg EA. Targets of cyclin-dependent protein kinases. Curr Opin Cell Biol 1993; 5: 187-93.
7. 1 cyclins. Cell 1993; 73: 1059-65.
8. 1 in human sarcomas. Cancer Res 1993; 53: 5535-41.
9. Motokura T, Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Dev 1993; 3: 5-10.
10. Maridor G, Gallant P, Golsteyn R, Nigg EA. Nuclear localization of vertebrate cyclin A correlates with its ability to form complexes with CDK catalytic subunits. J Cell Sci 1993; 106: 535-44.
11. Kamb A, Liu Q, Harshman K, Tavtigian S. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 416-7.
12. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994; 8: 27-32.
13. Mori T, Miura K, Aoki T et al. Frequent somatic mutation of the MTS1/CDK41 (multiple suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54: 3396-7.
14. ink4) in human breast carcinomas. Cancer Res 1994; 54: 5262-4.
15. Bonetta L. Open questions on p16. Nature 1994; 370: 180.
16. Spruck III CH, Gonzalez-Zulueta M, Shibata A et al. p16 gene in uncultured tumours. Nature 1994; 370: 183-4.
17. Cairns P, Mao L, Merlo A et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 415-16.
18. Hussussian CJ, Struewing JP, Goldstein AM et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15-21.
19. Tokuda Y, Saida T, Mukai K et al. Growth dynamics of acquired melanocytic nevi. J Am Acad Dermatol 1994; 31: 220-4.
20. Xiong Y, Hannon GJ, Zhang H et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
21. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
22. 1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
23. 1 cyclin-CDK protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
24. Noda A, Ning Y, Venable SF et al. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-8.
25. Hunter T. Braking the cycle. Cell 1993; 75: 839-41.
26. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM. TGF-β inhibition of CDK4 synthesis is linked to cell cycle arrest. Cell 1993; 74: 1009-20.
27. Tokuda Y, Mukai K, Matsuno Y et al. Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index. Arch Dermatol Res 1992; 284: 319-23.